Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kan akutt fotobiomodulasjon forbedre balanse og kognisjon hos personer med ataksi: en pilotgjennomførbarhetsstudie med placebokontrollert randomisert forsøk.

20. september 2026 oppdatert av: Jonathan Sinclair, University of Central Lancashire

Kan akutt fotobiomodulasjon forbedre balanse og kognisjon hos personer med ataksi: en pilotstudie for gjennomførbarhet med placebo randomisert kontrollert studie.

Cerebellar ataxias cause progressive impairments in balance, gait coordination, motor timing, and cognitive functions such as attention and executive control (Buckner, 2013; Salmi et al., 2010; Timmann & Daum, 2007). These symptoms substantially reduce independence and quality of life, and current treatments remain limited. There is an urgent need for safe, low-burden interventions that can support everyday functioning and potentially enhance compensatory neural processes.

Transcranial photobiomodulation (tPBM) uses red and near-infrared light (600-1100 nm) to modulate mitochondrial cytochrome-c oxidase, increasing ATP production, reducing oxidative stress, and improving cerebral blood flow (Hamblin, 2016; Salehpour et al., 2019). Several studies show that tPBM can acutely improve cognitive performance and motor control in both healthy adults and clinical groups (Barrett & Gonzalez-Lima, 2013; Chan et al., 2019; Henderson & Morries, 2017). A growing neurobiological literature suggests that light can penetrate posterior cortical areas sufficiently to modulate networks involving cerebellar-cortical loops (Jagdeo et al., 2012).

Importantly for ataxia, preliminary work shows that tPBM may acutely improve balance stability and gait metrics in older adults and patients with neurological conditions (Moro et al., 2022; Shin et al., 2021). In our own laboratory, we have observed immediate improvements in sway range and cognitive control in older adults after a 24-minute tPBM session applied over midline and posterior scalp regions. These medium to large size effects are consistent with enhanced sensorimotor integration and improved control of attention in distracting environments.

Given that individuals with cerebellar ataxia experience both motor incoordination and difficulties in maintaining cognitive stability under distracting conditions, tPBM is a promising non-pharmacological intervention worth preliminary investigation.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Studietype

Intervensjonell

Registrering (Antatt)

20

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18-70 years (inclusive)
  • Diagnosis of ataxia
  • Able to walk independently for at least 5 minutes, with or without an assistive device
  • Able to stand safely for balance testing, with or without an assistive device
  • Hemodynamically stable (stable blood pressure and heart rate at rest)
  • On a stable medication regimen for ≥4 weeks prior to enrolment
  • Sufficient vision and hearing (with usual aids if required) to complete balance and cognitive assessments
  • Able to complete study questionnaires and cognitive tasks (with assistance for reading/writing if required)
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Current or past history of head injury
  • Use of medications acting on the central nervous system
  • Active skin conditions on the forehead or scalp
  • Any other major neurological disorder that could independently affect balance or cognition
  • Ongoing brain stimulation therapy
  • History of migraines
  • Sensitive skin, allergies

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Sham Comparator: Sham photobiomodulation

Sham photobiomodulation. The sham device will follow the same protocol but without active light emission.

The sham device will follow the same protocol but without active light emission.

Eksperimentell: Photobiomodulation

Acute photobiomodulation Twenty-four-minute photobiomodulation stimulation (twelve minutes at 670 nm followed by twelve minutes at 810 nm).

Photobiomodulation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
n-1-back (deviation)
Tidsramme: Baseline

The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.

Baseline
n-1-back (deviation)
Tidsramme: 1 hour

The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.

1 hour

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
n-2-back (deviation)
Tidsramme: Baseline

The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.

Baseline
n-2-back (deviation)
Tidsramme: 1 hour

The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.

1 hour
n-1-back (post-deviation)
Tidsramme: Baseline

The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.

Baseline
n-1-back (post-deviation)
Tidsramme: 1 hour

The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.

1 hour
n-2-back (post-deviation)
Tidsramme: Baseline

The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.

Baseline
n-2-back (post-deviation)
Tidsramme: 1 hour

The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.

1 hour
n-1-back (post-target)
Tidsramme: Baseline

The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.

Baseline
n-1-back (post-target)
Tidsramme: 1 hour

The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.

1 hour
n-2-back (post-target)
Tidsramme: Baseline

The n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.

Baseline
n-2-back (post-target)
Tidsramme: 1 hour

The n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.

1 hour
n-1-back (load)
Tidsramme: Baseline

The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.

Baseline
n-1-back (load)
Tidsramme: 1 hour

The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.

1 hour
n-2-back (post-load)
Tidsramme: Baseline

The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.

Baseline
n-2-back (post-load)
Tidsramme: 1 hour

The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.

1 hour
Coop-Wonka chart
Tidsramme: Baseline

The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

Baseline
Coop-Wonka chart
Tidsramme: 1 hour

The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

1 hour
Beck Depression Inventory
Tidsramme: Baseline

Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

Baseline
Beck Depression Inventory
Tidsramme: 1 hour

Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

1 hour
Pittsburgh Sleep Quality Index
Tidsramme: Baseline

The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

Baseline
Pittsburgh Sleep Quality Index
Tidsramme: 1 hour

The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

1 hour
State Trait Anxiety Inventory
Tidsramme: Baseline

The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

Baseline
State Trait Anxiety Inventory
Tidsramme: 1 hour

The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

1 hour
Insomnia Severity Index
Tidsramme: Baseline

The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

Baseline
Insomnia Severity Index
Tidsramme: 1 hour

The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

1 hour
Epworth Sleepiness Scale
Tidsramme: Baseline

The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

Baseline
Epworth Sleepiness Scale
Tidsramme: 1 hour

The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

1 hour
Everyday Memory Errors Questionnaire
Tidsramme: Baseline

The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.

Baseline
Everyday Memory Errors Questionnaire
Tidsramme: 1 hour

The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.

1 hour
Falls Efficacy
Tidsramme: Baseline

The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.

Baseline
Falls Efficacy
Tidsramme: 1 hour

The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.

1 hour
Anterior-posterior balance
Tidsramme: Baseline

The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.

Baseline
Anterior-posterior balance
Tidsramme: 1 hour

The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.

1 hour
Medio-lateral balance
Tidsramme: Baseline

The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.

Baseline
Medio-lateral balance
Tidsramme: 1 hour

The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.

1 hour

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

10. desember 2027

Datoer for studieregistrering

Først innsendt

8. desember 2025

Først innsendt som oppfylte QC-kriteriene

8. desember 2025

Først lagt ut (Faktiske)

22. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere